SEC ownership of ACHIEVE LIFE SCIENCES, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000949858.

Comparable stake leader

TPG GP A, LLC

Disclosed value leader

TPG GP A, LLC

Comparable rows

50/50

Latest evidence

30 Apr 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
TPG GP A, LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Apr 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0000949858
Issuer location
Seattle, WA

Ownership snapshot

Top shareholders of ACHIEVE LIFE SCIENCES, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
TPG GP A, LLC
Disclosed value leader
TPG GP A, LLC
Comparable rows
50/50
Latest evidence
30 Apr 2026
13D/G 3/4/5 13F Lead comparable stake: 13% 13D/G row: TPG GP A, LLC Showing 1-8 of 50 holder rows.

Quick read

TPG GP A, LLC leads the comparable SEC ownership view at 13%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens TPG GP A, LLC's linked filing trail.
Comparable ownership Top 5
TPG GP A, LLC 13%
venBio Global Strategic Fund V, L.P. 10%
Paradigm Biocapital Advisors LP 9.2%
Frazier Life Sciences Public Fund... 6.5%
FRANKLIN RESOURCES INC 6.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
TPG GP A, LLC
13D/G 3/4/5
10%+ Owner
13%
$40,440,170
13,755,160 shares
$0 17 Apr 2025
venBio Global Strategic Fund V, L.P.
13D/G
10%
$31,567,712
10,737,317 shares
$0 15 Apr 2026
Paradigm Biocapital Advisors LP
13D/G
9.2%
$29,116,913
9,903,712 shares
$0 17 Apr 2026
Frazier Life Sciences Public Fund, L.P.
13D/G
6.5%
$19,479,817
6,625,788 shares
$0 17 Apr 2026
FRANKLIN RESOURCES INC
13D/G 13F
Company
6.2%
$22,801,922
6,369,252 shares
+$211 30 Apr 2026
Alyeska Investment Group, L.P.
13D/G
5.6%
$9,395,574
2,982,722 shares
-$6,098,715 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P.
13D/G
5.2%
$16,176,068
5,502,064 shares
$0 17 Apr 2026
VANGUARD GROUP INC
13D/G
The Vanguard Group
5%
$4,086,493
1,717,014 shares
$0 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$1,084,997.

Buys
$0
Insiders: 0
Sells
$1,084,997
Insiders: 6
Net
-$1,084,997
Shares: -381,972
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 381,972
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 381,972 $0 $1,084,997 -$1,084,997

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 31 reporting-owner rows connected to ACHIEVE LIFE SCIENCES, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
31
Largest Forms 3/4/5 holder
TPG GP A, LLC
Net 12M change
-$1,084,997
Latest report
29 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
TPG GP A, LLC 10%+ Owner $20,220,085 Median 17 Apr 2026
Jon Winkelried 10%+ Owner $20,220,085 Median 17 Apr 2026
James G. Coulter 10%+ Owner $20,220,085 Median 17 Apr 2026
DIALECTIC CAPITAL MANAGEMENT, LP 10%+ Owner $19,519,500 Mixed 18 Nov 2022
Thomas B. King Director $2,542,793 -$387,407 -13% Mixed 04 Sep 2025
Richard Alistair Stewart Chief Executive Officer, Director $1,250,261 -$378,143 -23% Mixed 18 Sep 2025
Mark K. Oki Chief Financial Officer $990,144 -$146,175 -13% Mixed 18 Sep 2025
Cindy Jacobs President & CMO $797,270 -$76,532 -8.8% Mixed 04 Sep 2025
Jaime Xinos Chief Commercial Officer $573,176 -$57,766 -9.2% Mixed 04 Sep 2025
John Bencich CEO, Director $369,334 Mixed 16 Aug 2024
Jerry Wan Principal Accounting Officer $266,722 -$38,974 -13% Mixed 04 Sep 2025
Mark Lawrence Rubinstein Chief Medical Officer $185,724 Mixed 01 Jan 2026
Craig Donnelly Chief Operations Officer $165,495 Mixed 01 Oct 2025
Anthony Clarke Cso $39,490 Mixed 28 Apr 2022
Aaron Royston Director Mixed 17 Apr 2026
Christopher Nathan Martin Director Mixed 11 May 2026
Jeffrey S. Farrow Director Mixed 29 May 2026
Reid Alexander Waldman Director Mixed 29 May 2026
Stuart Duty Director Mixed 06 Jun 2025
Nancy R. Phelan Director Mixed 06 Jun 2025

Recent insider transactions for ACHIEVE LIFE SCIENCES, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Reid Alexander Waldman ACHV Stock Option (right to buy) Award 47,250 47,250 29 May 2026 Direct
Jeffrey S. Farrow ACHV Stock Option (right to buy) Award 47,250 47,250 29 May 2026 Direct
Christopher Nathan Martin ACHV Stock Option (right to buy) Award 47,250 47,250 11 May 2026 Direct
Andrew D. Goldberg ACHV Performance Restricted Stock Unit (PRSU) Award 11,706,270 11,706,270 18 Apr 2026 Direct
Andrew D. Goldberg ACHV Stock Option (right to buy) Award 3,601,929 3,601,929 18 Apr 2026 Direct
Andrew D. Goldberg ACHV Restricted Stock Unit (RSU) Award 1,800,965 1,800,965 18 Apr 2026 Direct
Mark Lawrence Rubinstein ACHV Stock Option (right to buy) Award 180,000 180,000 28 Jan 2026 Direct
Craig Donnelly ACHV Stock Option (right to buy) Award 180,000 180,000 28 Jan 2026 Direct
Jaime Xinos ACHV Stock Option (right to buy) Award 180,000 180,000 28 Jan 2026 Direct
Jerry Wan ACHV Stock Option (right to buy) Award 70,300 70,300 28 Jan 2026 Direct
Richard Alistair Stewart ACHV Stock Option (right to buy) Award 645,000 645,000 28 Jan 2026 Direct
Mark K. Oki ACHV Stock Option (right to buy) Award 180,000 180,000 28 Jan 2026 Direct
Erik Atkisson ACHV Stock Option (right to buy) Award 250,000 250,000 04 Dec 2025 Direct
Craig Donnelly ACHV Stock Option (right to buy) Award 50,000 50,000 01 Oct 2025 Direct
Mark K. Oki ACHV Common Stock Sale -28.1% $146,175 $2.92 -50,060 127,940 18 Sep 2025 Direct
Mark K. Oki ACHV Common Stock Options Exercise 1680% 168,000 178,000 18 Sep 2025 Direct
Mark K. Oki ACHV Performance Restricted Stock Unit (PRSU) Options Exercise -100% -168,000 0 18 Sep 2025 Direct
Richard Alistair Stewart ACHV Common Stock Sale -36.1% $378,143 $2.92 -129,501 228,875 18 Sep 2025 Direct
Richard Alistair Stewart ACHV Common Stock Options Exercise 488.7% 297,500 358,376 18 Sep 2025 Direct
Richard Alistair Stewart ACHV Performance Restricted Stock Unit (PRSU) Options Exercise -100% -297,500 0 18 Sep 2025 Direct
Mark K. Oki ACHV Performance Restricted Stock Unit Award -100% -168,000 0 04 Sep 2025 Direct
Richard Alistair Stewart ACHV Performance Restricted Stock Unit Award -100% -297,500 0 04 Sep 2025 Direct
Jerry Wan ACHV Common Stock Sale -30.1% $38,974 $2.77 -14,070 32,694 04 Sep 2025 Direct
Jerry Wan ACHV Common Stock Options Exercise 269.3% 34,100 46,764 04 Sep 2025 Direct
Jerry Wan ACHV Performance Restricted Stock Unit (PRSU) Options Exercise -100% -34,100 0 04 Sep 2025 Direct
Thomas B. King ACHV Common Stock Sale -30.7% $387,407 $2.77 -139,858 315,142 04 Sep 2025 Direct
Thomas B. King ACHV Common Stock Options Exercise 455,000 455,000 04 Sep 2025 Direct
Thomas B. King ACHV Performance Restricted Stock Unit (PRSU) Options Exercise -100% -455,000 0 04 Sep 2025 Direct
Cindy Jacobs ACHV Common Stock Sale -19.3% $76,532 $2.77 -27,629 115,585 04 Sep 2025 Direct
Cindy Jacobs ACHV Common Stock Options Exercise 331.2% 110,000 143,214 04 Sep 2025 Direct
Cindy Jacobs ACHV Performance Restricted Stock Unit (PRSU) Options Exercise -100% -110,000 0 04 Sep 2025 Direct
Jaime Xinos ACHV Common Stock Sale -21.9% $57,766 $2.77 -20,854 74,432 04 Sep 2025 Direct
Jaime Xinos ACHV Common Stock Options Exercise 262.5% 69,000 95,286 04 Sep 2025 Direct
Jaime Xinos ACHV Performance Restricted Stock Unit (PRSU) Options Exercise -100% -69,000 0 04 Sep 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .